© SEP 2026 | IRE Journals | Volume 10 Issue 3 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I3-1722919

Formulation and Evaluation of Riboflavin: A Comprehensive Review

BIVEK KUMAR GUPTA[1], DR. RAJEEV RANJAN[2], DR. DHARMENDRA KUMAR[3]
[1] *Research Scholar, Narayan Institute of Pharmacy (Faculty of Pharmacy), Gopal Narayan Singh University, Jamuhar, Sasaram, Bihar, India*
[2] *Assistant Professor, Narayan Institute of Pharmacy (Faculty of Pharmacy), Gopal Narayan Singh University, Jamuhar, Sasaram, Bihar, India*
[3] *Principal, Narayan Institute of Pharmacy (Faculty of Pharmacy), Gopal Narayan Singh University, Jamuhar, Sasaram, Bihar, India*

Abstract- Riboflavin (vitamin B2) is a water-soluble, photosensitive isoalloxazine derivative that serves as the biochemical precursor of the essential flavocoenzymes flavin mononucleotide and flavin adenine dinucleotide, and is thereby indispensable to cellular oxidation-reduction metabolism, energy production, and the activation of several other micronutrients. Clinically, riboflavin is central to the prevention and treatment of ariboflavinosis, has demonstrated efficacy as a prophylactic agent in migraine, and, in a markedly different application, underpins the photochemical mechanism of ultraviolet-A corneal collagen cross-linking used to arrest progressive keratoconus. From a pharmaceutical technology standpoint, riboflavin presents a distinctive formulation challenge: it is only sparingly soluble in water, and, more importantly, it is highly sensitive to light and, to a lesser extent, heat, undergoing pH-dependent photodegradation to inactive products such as lumichrome and lumiflavin. This review consolidates current literature on the chemistry, photochemistry, biochemical role, absorption and metabolism, clinical applications, and industrial microbial production of riboflavin, before turning to the pharmaceutical formulation science required to develop a stable, bioavailable riboflavin dosage form, including preformulation and drug-excipient compatibility assessment, photostabilisation strategies such as complexation and protective packaging, tablet and novel (liposomal, nanoencapsulated) delivery system design, and the analytical and stability evaluation parameters, spanning pre-compression, post-compression, chemical, and photostability testing, that such a product must satisfy. The review is intended as a consolidated reference for formulation scientists undertaking the development and quality evaluation of riboflavin-containing pharmaceutical products.

Keywords: Riboflavin; vitamin B2; photodegradation; photostabilisation; tablet formulation; flavin coenzymes; migraine prophylaxis; corneal cross-linking; stability evaluation

I. INTRODUCTION

Riboflavin, first isolated in the early twentieth century as the heat-stable, water-soluble factor distinct from thiamine, is now recognised as one of the eight B-complex vitamins and as an obligatory dietary nutrient for humans, since mammalian cells lack the biosynthetic pathway present in plants, fungi, and many bacteria. Its central biochemical importance derives not from the free vitamin itself but from its two coenzyme derivatives, flavin mononucleotide and flavin adenine dinucleotide, which together participate as prosthetic groups in a very large number of flavoprotein-catalysed oxidation-reduction reactions spanning carbohydrate, lipid, and amino acid metabolism, mitochondrial electron transport, and the activation of other B-vitamins. [1,2,3]

Despite this fundamental biological importance and its wide availability in dairy products, eggs, green leafy vegetables, and fortified cereals, riboflavin deficiency, termed ariboflavinosis, remains a significant public health problem in many low- and middle-income countries and persists at a subclinical level even in high-income settings, while pharmacological doses of riboflavin, well above nutritional requirements, have separately been investigated and adopted for indications as diverse as migraine prophylaxis and, through an entirely distinct photochemical mechanism, corneal collagen cross-linking in progressive keratoconus. [4,5,6]

© SEP 2026 | IRE Journals | Volume 10 Issue 3 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I3-1722919

From a pharmaceutical technology perspective, riboflavin is a formulator's paradox: it is a chemically simple, inexpensive, and well-characterised small molecule, yet its pronounced sensitivity to light, and to a lesser degree heat and pH extremes, means that a poorly designed dosage form can lose a clinically meaningful fraction of its potency well before the labelled expiry date, with consequent implications for both nutritional and therapeutic efficacy. This review was undertaken to consolidate the scientific literature relevant to the formulation and evaluation of riboflavin, beginning with its chemistry, biochemistry, and clinical pharmacology, and proceeding to a detailed examination of the formulation strategies and evaluation parameters that underpin a pharmaceutically sound riboflavin product. [7,8]

II. CHEMISTRY AND PHYSICOCHEMICAL PROPERTIES OF RIBOFLAVIN

2.1 Structure and General Properties

Riboflavin is chemically 7,8-dimethyl-10-(D-ribityl)isoalloxazine, consisting of a tricyclic isoalloxazine (dimethylbenzo-pteridine-dione) chromophore substituted at the nitrogen-10 position with a D-ribityl side chain; this planar, conjugated ring system is responsible both for the characteristic yellow-orange colour and intense green fluorescence of riboflavin solutions and for its pronounced photochemical reactivity. The compound occurs as a yellow to orange-yellow crystalline powder with a slightly bitter taste, is only sparingly soluble in water at neutral pH, with solubility increasing appreciably at strongly acidic or alkaline pH, and is more soluble in dilute alkali than in dilute acid, a property that has practical implications for aqueous formulation and for the choice of vehicle in liquid dosage forms. [9]

Riboflavin displays characteristic ultraviolet-visible absorption maxima, most notably in the region of 445 nanometres, which underlies both its visible colour and the wavelength range of light most implicated in its photodegradation, together with strong native fluorescence that is itself exploited analytically to monitor the extent of photodegradation, since loss of fluorescence intensity and its replacement by the distinct fluorescence signatures of the photoproducts lumichrome and lumiflavin can be used to track degradation in real time. Table 1 summarises the principal physicochemical attributes of riboflavin of relevance to pharmaceutical formulation. [10]

Table 1. Key Physicochemical Properties of Riboflavin Relevant to Formulation

Property	Characteristic	Formulation Relevance
Chemical nature	7,8-Dimethyl-10-(D-ribityl)isoalloxazine (flavin derivative)	Planar conjugated chromophore underlies colour, fluorescence and photoreactivity
Molecular weight	~376.4 g/mol	Relevant to dose calculation and coenzyme (FMN/FAD) conversion
Appearance	Yellow to orange-yellow crystalline powder; bitter taste	May require taste-masking in chewable/liquid forms
Aqueous solubility	Sparingly soluble in water at neutral pH; more soluble in dilute alkali than dilute acid	Vehicle pH selection influences both solubility and photostability
UV-Vis absorption	Absorption maxima including ~445 nm (visible region)	Defines the wavelength range most implicated in photodegradation
Fluorescence	Strong native green fluorescence, quenched/altered on degradation	Enables fluorescence-based monitoring of photostability
Principal degradation products	Lumichrome (acidic/neutral pH); lumiflavin (alkaline pH)	Serve as stability-indicating markers in analytical methods
Typical oral dose range	1-4 mg/day (nutritional); up to 400 mg/day (migraine prophylaxis)	Wide dose range demands flexible, robust dosage-form design

2.2 Photochemistry and Degradation Pathways

Riboflavin is widely regarded as one of the most photolabile substances encountered in pharmaceutical

© SEP 2026 | IRE Journals | Volume 10 Issue 3 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I3-1722919

and food science, and its degradation behaviour has been the subject of extensive kinetic and spectroscopic investigation. On absorption of ultraviolet or visible light, riboflavin is promoted to an excited singlet state and subsequently to a longer-lived excited triplet state; the fate of this excited species, and hence the identity of the resulting photoproduct, is strongly dependent on the pH of the medium, with photodegradation under acidic or neutral conditions proceeding predominantly through photoreduction and cleavage of the ribityl side chain to yield the non-fluorescent product lumichrome, whereas under alkaline conditions photodissociation additionally yields lumiflavin, a smaller, still fluorescent degradation product. [9,11,12]

Time-resolved mass spectrometry and gas-phase infrared multiple-photon dissociation spectroscopy studies have further characterised the transient intermediate formylmethylflavin along the photodegradation pathway and have demonstrated that riboflavin readily forms dimers in solution, with photolysis of the dimeric species proceeding at an enhanced rate relative to the monomer, an observation that helps explain the pronounced concentration-dependence of riboflavin photostability observed in more concentrated pharmaceutical and food formulations. [9,13]

Beyond light, a broad range of formulation and environmental variables have been shown to modulate the rate of riboflavin degradation, including the intensity and spectral distribution of the radiation source, solution pH, the presence and concentration of dissolved oxygen, buffer species and ionic strength, solvent polarity and viscosity, and temperature, with thermal degradation pathways operating in parallel with, but generally more slowly than, photochemical pathways. A comprehensive review of these factors concluded that an optimally selected pH and buffer system, together with the incorporation of stabilisers or complexing agents and appropriate light-protective packaging, offers the most effective overall strategy for stabilising riboflavin in aqueous and solid pharmaceutical preparations, a conclusion of direct relevance to the formulation strategies discussed in Section 7. Figure 1 summarises the principal photodegradation pathways and the environmental factors that influence them. [9,11]



Figure 1. Schematic overview of the photodegradation pathways of riboflavin.

III. BIOCHEMICAL ROLE AND PHYSIOLOGICAL FUNCTIONS

3.1 Coenzyme Forms: FMN and FAD

Free riboflavin itself has essentially no direct catalytic activity; rather, its physiological importance depends on its intracellular conversion, catalysed sequentially by flavokinase and FAD synthase, first to flavin mononucleotide through ATP-dependent phosphorylation and subsequently to flavin adenine dinucleotide through ATP-dependent adenylylation. These two flavocoenzymes act as prosthetic groups for a very large family of flavoprotein oxidoreductases, participating in reactions central to the tricarboxylic acid cycle, fatty acid beta-oxidation, the mitochondrial electron transport chain, and amino acid catabolism, and thereby occupying a position of unusual centrality within cellular bioenergetics relative to many other micronutrients. [14,15,16]

Flavocoenzymes additionally participate in the metabolic activation of other vitamins, since FAD-dependent methylenetetrahydrofolate reductase is required for folate metabolism and the remethylation of homocysteine, FMN-dependent pyridoxine phosphate oxidase converts inactive forms of vitamin B6 to its active coenzyme form, and FAD-dependent kynurenine hydroxylase participates in the conversion of tryptophan to niacin, so that riboflavin status can indirectly influence the functional adequacy of several other micronutrient pathways. [17]

3.2 Absorption, Transport, and Metabolism

Dietary riboflavin occurs predominantly bound as FAD and FMN rather than as the free vitamin; these coenzyme forms are released from dietary protein by gastric acid and are subsequently hydrolysed to free riboflavin by non-specific brush-border phosphatases, including FMN phosphatase and FAD pyrophosphatase, localised on the ileal enterocyte membrane. Free riboflavin is then absorbed by a specific, saturable, carrier-mediated transport process, predominantly via the riboflavin transporter RFVT3, encoded by SLC52A3, with the absorptive process becoming saturated at approximately twenty to thirty milligrams from a single meal or dose, an important pharmacokinetic ceiling that limits the incremental absorption achievable from very high single oral doses. [18,19,20]

Within the enterocyte, absorbed riboflavin can be re-phosphorylated to FMN by flavokinase and further converted to FAD, or exported into the portal circulation by basolaterally expressed riboflavin transporters, with circulating riboflavin and its coenzymes bound predominantly to plasma albumin and immunoglobulins; a related transporter, RFVT2, mediates riboflavin uptake into the brain and other tissues including the pancreas, liver, and muscle. Because most riboflavin is not stored to any substantial degree in the body, excess intake is efficiently excreted unchanged in the urine, producing the characteristic bright yellow discolouration used clinically as a rough indicator of adequate or supra-adequate intake, while inherited mutations in the riboflavin transporter genes cause riboflavin transporter deficiency, a severe neurodegenerative disorder that responds, often dramatically, to high-dose riboflavin supplementation. [21,22,23]

IV. RIBOFLAVIN DEFICIENCY AND CLINICAL SIGNIFICANCE

4.1 Ariboflavinosis: Causes and Manifestations

Riboflavin deficiency, or ariboflavinosis, arises most commonly from inadequate dietary intake, malabsorptive gastrointestinal conditions, chronic alcohol use, which impairs both digestion and intestinal absorption of the vitamin, and, less commonly, from inherited defects of riboflavin transport or utilisation; because riboflavin deficiency frequently co-occurs with deficiencies of other B-complex vitamins that share common dietary sources, its clinical manifestations can overlap with, and be modified by, concurrent deficiency states. Classical clinical deficiency presents with mucocutaneous manifestations including cheilosis, angular stomatitis, glossitis with a swollen, reddened tongue, and a seborrheic, greasy dermatitis affecting the nasolabial folds, scrotum, or vulva, together with a normocytic anaemia characterised by erythroid hypoplasia. [4,5,24]

Beyond these hallmark mucocutaneous and haematological findings, riboflavin deficiency has additionally been associated with ocular manifestations including corneal vascularisation and photophobia, neurological symptoms, migraine headache, reduced physical performance and

© SEP 2026 | IRE Journals | Volume 10 Issue 3 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I3-1722919

developmental impairment in children, and, in more recent research, a possible protective association between adequate riboflavin status and reduced psoriasis risk, together with experimentally demonstrated effects on the gut microbiome and on histamine-mediated pruritus. In rare inborn errors affecting flavin metabolism, including multiple acyl-coenzyme A dehydrogenase deficiency and riboflavin transporter deficiency, pharmacological riboflavin supplementation can produce marked clinical improvement or stabilisation, underscoring the therapeutic as well as nutritional relevance of the vitamin. [25,26,27,28]

4.2 At-Risk Populations and Epidemiology

Populations at elevated risk of riboflavin deficiency include pregnant and lactating women, whose requirements increase to support fetal and infant growth, infants and school-age children in resource-limited settings, the elderly, in whom reduced dietary variety and intestinal absorptive efficiency both contribute, and individuals with chronic alcohol use disorder or malabsorptive conditions such as coeliac disease. Epidemiological surveys indicate that while severe clinical ariboflavinosis is now uncommon outside low-income settings, subclinical biochemical deficiency, detected through reduced erythrocyte glutathione reductase activation coefficient, remains substantially more prevalent worldwide, including in some high-income country populations, a distinction of practical importance when designing supplementation and fortification programmes. [4,5,24]

V. THERAPEUTIC AND CLINICAL APPLICATIONS OF RIBOFLAVIN

5.1 Nutritional Supplementation and Deficiency States

The primary and best-established therapeutic use of riboflavin remains the prevention and correction of nutritional deficiency, typically achieved with oral doses in the range of one to four milligrams daily where gastrointestinal absorption is normal, delivered either as a single-ingredient tablet or capsule or, more commonly in clinical practice, as a component of combined vitamin B-complex or multivitamin formulations, reflecting the frequent co-occurrence of multiple B-vitamin deficiencies in at-risk populations. Because the intestinal absorption of riboflavin saturates at a defined dose per meal, deficiency correction is generally more effectively achieved through divided dosing across the day than through a single large bolus dose. [29,30]

5.2 Migraine Prophylaxis

One of the most extensively studied pharmacological applications of riboflavin outside its nutritional role is migraine prophylaxis, motivated by evidence that a deficit of mitochondrial energy metabolism may contribute to migraine pathogenesis and that riboflavin, as the precursor of the flavocoenzymes central to mitochondrial oxidative metabolism, might correct this deficit. A landmark randomised, placebo-controlled trial found that high-dose riboflavin, four hundred milligrams daily for three months, was superior to placebo in reducing migraine attack frequency and headache days, with fifty-nine percent of riboflavin-treated patients classified as fifty-percent responders compared with fifteen percent on placebo, and with only minor, non-serious adverse events reported. [31,32]

Subsequent randomised trials and systematic reviews, including comparisons of riboflavin against active comparators such as propranolol and sodium valproate and dose-response meta-analyses pooling data across adult and paediatric populations, have generally supported a beneficial effect of riboflavin on migraine attack frequency, although the paediatric and adolescent evidence base has been comparatively more mixed, with some trials failing to demonstrate a significant benefit over placebo. Given its low cost, wide availability, and excellent tolerability relative to conventional migraine prophylactic agents, riboflavin continues to be recommended by several headache management guidelines as a reasonable adjunct or first-line prophylactic option, particularly for patients seeking to avoid the adverse effect burden associated with pharmacological alternatives. [33,34,35,36]

© SEP 2026 | IRE Journals | Volume 10 Issue 3 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I3-1722919

Table 2. Representative Clinical and Application Contexts for Riboflavin

Application / Setting	Study Design (Representative)	Regimen	Key Reported Outcome
Nutritional deficiency (ariboflavinosis)	Clinical/nutritional management	1-4 mg/day oral, often as part of B-complex	Resolution of cheilosis, glossitis, dermatitis and anaemia
Adult migraine prophylaxis	Randomised, placebo-controlled trial (3 months)	400 mg/day oral riboflavin	Superior to placebo for attack frequency and headache days; 59% responder rate
Adult migraine prophylaxis (active comparator)	Open-label randomised controlled trial	Riboflavin vs oral propranolol	Comparable prophylactic effect reported across pooled trial data
Paediatric/adolescent migraine	Randomised, double-blind, placebo-controlled trial	400 mg/day oral riboflavin	Mixed results across trials; some show benefit, others no significant effect
Keratoconus (corneal collagen cross-linking)	Prospective non-randomised clinical study (Dresden protocol)	Topical riboflavin + UV-A 3 mW/cm2, 30 min	~70% stabilisation/flattening of maximal keratometry
Keratoconus safety evaluation	Prospective interventional study	UV-A/riboflavin CXL, 12-month follow-up	Stable corneal endothelial cell density and foveal thickness
Riboflavin transporter deficiency	Case-based clinical management	High-dose oral riboflavin supplementation	Significant clinical improvement/stabilisation in majority of patients

5.3 Corneal Collagen Cross-Linking

A therapeutic application of riboflavin that is mechanistically unrelated to its coenzyme or nutritional role is corneal collagen cross-linking, a minimally invasive procedure developed to halt the progression of keratoconus and other corneal ectatic disorders. In the standard, or Dresden, protocol, topical riboflavin solution is instilled onto the de-epithelialised corneal stroma for approximately thirty minutes to achieve adequate stromal saturation, after which the cornea is irradiated with ultraviolet-A light at a defined irradiance and total energy dose; riboflavin serves the dual function of acting as a photosensitiser that generates reactive oxygen species inducing new covalent cross-links between stromal collagen fibrils, thereby biomechanically stiffening the cornea, and of absorbing and attenuating ultraviolet-A light to protect the corneal endothelium and deeper ocular structures from direct radiation damage. [37,38,39]

Clinical outcome studies spanning more than two decades since the first published pilot series have demonstrated that corneal cross-linking achieves stabilisation or flattening of maximal corneal keratometry in a majority of treated eyes, with reported success rates in the region of seventy percent and a good long-term safety profile with respect to corneal endothelial cell density and central retinal thickness; regulatory approval of a proprietary riboflavin-UV-A cross-linking system by the United States Food and Drug Administration in 2016, based on multiple prospective randomised trials, has further embedded this application within standard ophthalmic practice for progressive keratoconus and secondary corneal ectasia. [37,40,41,42]

5.4 Emerging and Adjunct Applications

Beyond its established roles, riboflavin has been investigated for a range of emerging applications, including modulation of histamine-dependent itch through effects on transient receptor potential vanilloid 1 channels, antioxidant and anti-inflammatory activity, and possible chemopreventive effects mediated through modulation of retinol metabolism, alongside continuing interest in its role in maintaining normal retinal structure and function, where experimental dietary deficiency models have demonstrated cone photoreceptor dysfunction and degeneration. While these applications remain at earlier stages of clinical validation relative to nutritional supplementation, migraine prophylaxis, and corneal cross-linking, they illustrate the breadth of pharmacological interest that a simple, low-cost, well-tolerated vitamin continues to attract. [43,28]

VI. INDUSTRIAL PRODUCTION OF RIBOFLAVIN

Whereas riboflavin was historically manufactured by multistep chemical synthesis, essentially the entire global commercial supply is now produced by large-scale microbial fermentation, a shift driven by the substantially lower cost, reduced environmental burden, and higher achievable titres of biotechnological production relative to chemical routes. The principal industrial production organisms are the filamentous fungus Ashbya gossypii, the Gram-positive bacterium Bacillus subtilis, and yeasts of the genus Candida, particularly Candida famata, each of which has been subjected to extensive classical mutagenesis and, more recently, rational metabolic engineering to deregulate purine biosynthesis, increase flux through the riboflavin biosynthetic pathway from guanosine triphosphate and ribulose-5-phosphate precursors, and thereby achieve commercially viable titres reported in the range of fourteen to twenty grams per litre for the principal industrial strains. [44,45,46]

This mature, low-cost fermentation-based supply chain, dominated by a small number of major global manufacturers, underlies the very low bulk price of pharmaceutical- and food-grade riboflavin relative to many other vitamins and pharmaceutical actives, and is an important practical consideration for formulators, since it means that raw material cost is rarely a limiting factor in riboflavin product development and that formulation effort can instead be concentrated on the photostability and bioavailability challenges discussed in the sections that follow. [44,47,48]

VII. FORMULATION DEVELOPMENT CONSIDERATIONS

7.1 Preformulation and the Central Photostability Challenge

Preformulation development of any riboflavin-containing dosage form must begin from the recognition that photostability, rather than chemical stability in the conventional sense, represents the principal degradation risk to be managed, since, as detailed in Section 2.2, riboflavin degrades readily on exposure to ordinary room and daylight illumination even at ambient temperature. Preformulation studies should therefore explicitly include a photoreactivity screen of the bulk drug substance and of prototype formulations under defined irradiation conditions, informed by the internationally harmonised ICH Q1B guideline on photostability testing, in addition to the more conventional preformulation assessments of solubility, particle size and morphology, and drug-excipient compatibility performed by Fourier-transform infrared spectroscopy and differential scanning calorimetry. [9,49,50]

Compatibility screening is of particular importance for riboflavin because several commonly used pharmaceutical excipients have themselves been shown to modulate its photodegradation rate, sometimes accelerating rather than retarding it; for example, macromolecular excipients such as polyvinylpyrrolidone, polysorbate 80, and sodium decyl sulfate have been reported to enhance the rate of aerobic photobleaching of riboflavin, so that excipient selection for a riboflavin product cannot rely solely on conventional compatibility criteria but must also incorporate photostability as an explicit screening endpoint. [51,52]

7.2 Photostabilisation Strategies

Several complementary formulation strategies have been developed and validated in the literature for mitigating riboflavin photodegradation. Molecular complexation is among the most extensively studied: caffeine has been shown to form a monomeric complex with riboflavin that substantially inhibits its photolysis across a wide pH range, with kinetic studies establishing that the inhibitory effect is greatest around pH 6 where the caffeine-riboflavin complex shows its highest stability constant, although the same body of work has also shown that certain buffer species, including phosphate at higher concentrations, can themselves accelerate an alternative photoaddition degradation pathway even in the presence of caffeine, underscoring the need for a holistic, rather than single-excipient, stabilisation strategy. [53,54,55]

Cyclodextrin inclusion complexation represents a second well-validated photostabilisation approach, with beta-cyclodextrin and related cyclodextrin derivatives shown to form inclusion complexes with riboflavin that measurably reduce its rate of photodegradation, a strategy that parallels the use of cyclodextrin complexation to photostabilise other light-sensitive drug substances. Encapsulation within liposomal or lipid-based delivery systems has been shown to be still more effective: riboflavin entrapped alone within dehydration-rehydration vesicle liposomes exhibited an approximately four-fold increase in photostability relative to free riboflavin in water, an effect that rose to approximately twenty-fold when riboflavin was first complexed with gamma-cyclodextrin before liposomal entrapment, and to over two-hundred-fold when co-entrapped with additional protective agents, illustrating that combined, multi-mechanism stabilisation strategies can achieve substantially greater protection than any single approach in isolation. [56,57,58]

At the level of the finished dosage form and its packaging, conventional pharmaceutical photostabilisation measures, including the use of amber or otherwise light-opaque primary containers, opaque or pigmented film coatings for tablets, and secondary packaging that excludes ambient light during storage and distribution, remain essential complements to excipient-level stabilisation strategies and are consistent with the general principles for photolabile pharmaceuticals set out in the major pharmacopoeias and in the ICH photostability testing framework. [49,59,60]

7.3 Tablet Formulation Design

For the conventional oral tablet, which remains the most widely used dosage form for riboflavin nutritional supplementation, formulation design follows established solid oral dosage form principles, with selection of diluents, binders, disintegrants, glidants, and lubricants guided by the flow, compressibility, and compatibility characteristics of riboflavin, and with particular attention, as discussed above, to whether any given excipient measurably affects photostability. Where rapid onset or improved swallowability is desired, riboflavin has, in common with many other actives, been incorporated into orally disintegrating tablet platforms using coprocessed superdisintegrants and formulated by direct compression, with formulation optimisation increasingly guided by Quality-by-Design and Design of Experiments methodologies that define a Quality Target Product Profile and systematically link critical material attributes and process parameters to the critical quality attributes of potency, dissolution, and physical robustness. [61,62]

Figure 2 presents a recommended, systematically staged workflow for the development of a photostable, bioavailable riboflavin dosage form, integrating the preformulation, photostabilisation, formulation design, and evaluation stages discussed throughout this section into a single coherent development pathway suitable for either a conventional tablet or an alternative delivery platform. [61,49]

7.4 Novel and Alternative Delivery Systems

Beyond the conventional tablet, a number of alternative delivery platforms have been explored for riboflavin, motivated variously by the desire to improve photostability, enhance bioavailability beyond the saturable intestinal absorption ceiling, or adapt the vitamin for food fortification and functional food applications. Nanoencapsulation and microencapsulation technologies, employing wall materials such as alginate, chitosan, gelatin, and starch-based or lipid-based carriers, have been used to protect riboflavin and other hydrophilic bioactives from environmental degradation during processing, storage, and gastrointestinal transit, while simultaneously masking any organoleptic drawbacks and enabling more controlled release profiles. [63,64,65]

Liposomal delivery systems, in particular, have attracted sustained interest for riboflavin because, as noted in Section 7.2, they combine a substantial intrinsic photoprotective effect with the general advantages of liposomal encapsulation, including a high surface-area-to-volume ratio that favours

© SEP 2026 | IRE Journals | Volume 10 Issue 3 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I3-1722919

efficient cellular uptake, enhanced colloidal stability, and compatibility with both pharmaceutical and functional food matrices; related work on riboflavin-loaded water-in-water emulsions stabilised by protein-polysaccharide liposomal systems has similarly demonstrated meaningfully improved retention of riboflavin fluorescence, and by extension chemical integrity, under ultraviolet irradiation relative to unencapsulated controls. [66,67,68]

In the food fortification domain, where riboflavin is one of several micronutrients commonly co-encapsulated with iron, folic acid, or fat-soluble vitamins to address multiple deficiencies simultaneously, nanoliposomal and microfluidic-based encapsulation techniques have been developed to achieve high encapsulation efficiency, controlled particle size, and improved shelf-life, illustrating the convergence of pharmaceutical and food-technology approaches to stabilising this particular vitamin. [69,70,71]

VIII. EVALUATION PARAMETERS

8.1 Pre-Compression and Preformulation Evaluation

Prior to compression, the powder blend or granulate intended for a riboflavin tablet must be characterised for the standard pre-compression parameters used across solid oral dosage form development, including bulk and tapped density, from which the Carr's compressibility index and Hausner ratio are derived as indirect indicators of powder flow, together with direct measurement of the angle of repose and, where a wet or dry granulation process is used, granule size distribution; because riboflavin itself is a fine, cohesive crystalline powder, particular attention to flow-enhancing excipient selection and granulation strategy is generally required to achieve acceptable tablet weight uniformity at the compression stage. [72]

8.2 Post-Compression Tablet Evaluation

Following compression, riboflavin tablets, in common with solid oral dosage forms generally, must be evaluated against the standard pharmacopoeial panel of post-compression tests, comprising tablet hardness, typically targeted in the range of four to ten kilograms-force for conventional oral tablets since inadequate hardness compromises mechanical integrity while excessive hardness can impair disintegration, friability, which should not exceed one percent weight loss to ensure the tablet withstands routine handling and transport, weight variation and content uniformity, assessed against pharmacopoeial limits to confirm consistent dose delivery across a batch, and disintegration time, with uncoated tablets generally required to disintegrate within thirty minutes and film-coated tablets permitted a longer interval. [72,73,74]
In-vitro dissolution testing, typically performed using a paddle or basket apparatus in an appropriate aqueous medium, provides a further, more discriminating measure of tablet performance and is of particular relevance for riboflavin given its limited aqueous solubility, since a formulation that disintegrates rapidly but releases the active substance slowly from an unfavourable crystalline or particulate form would not necessarily translate into adequate in-vivo absorption within the saturable window of intestinal riboflavin transport described in Section 3.2. Table 2 illustrates representative therapeutic and evaluation contexts in which these parameters, alongside clinical outcome measures, have been reported for riboflavin-based interventions. [75]

8.3 Analytical and Chemical Evaluation

Quantitative determination of riboflavin content and purity is most commonly performed by reverse-phase high-performance liquid chromatography with ultraviolet or fluorescence detection, methods that have been validated for riboflavin alone and in combination with other B-vitamins in a variety of matrices including multivitamin syrups, compound vitamin B tablets, plasma, and even food matrices such as mushrooms, generally following pharmacopoeial or closely related chromatographic conditions and validated according to ICH guidance for specificity, linearity, accuracy, precision, and robustness. Because riboflavin's principal degradation products, lumichrome and lumiflavin, are themselves chromatographically and spectroscopically distinguishable from the parent compound, a well-designed, stability-indicating HPLC assay can simultaneously quantify potency and detect the emergence of these specific degradation products, providing a considerably more informative quality-control tool than a simple non-selective spectrophotometric assay. [76,77,78,79]

Complementary spectrophotometric and multicomponent spectrophotometric methods, exploiting riboflavin's characteristic ultraviolet-visible absorption and fluorescence properties, continue to be used in both research and quality-control settings, particularly for kinetic photodegradation studies where rapid, repeated measurement is required, while identification testing and, where applicable, related-substance limits should be set with reference to the relevant pharmacopoeial monograph for the dosage form under development. [55,77]

8.4 Photostability and Long-Term Stability Testing

Given the centrality of photodegradation to riboflavin's stability profile, photostability testing performed in accordance with the ICH Q1B guideline is an essential, rather than optional, component of the stability evaluation programme for any riboflavin dosage form, involving controlled exposure of the drug substance and finished product, in both its proposed primary packaging and, where relevant, unpacked, to defined quantities of visible and ultraviolet-A illumination, with assay, appearance, and related-substance content assessed before and after exposure to establish whether the proposed formulation and packaging combination provides adequate protection under realistic handling and storage conditions. [49,60]

In parallel, conventional long-term and accelerated stability studies conducted under the ICH Q1A framework, at the internationally harmonised long-term and accelerated temperature and humidity conditions and over the standard series of testing intervals, remain necessary to establish an overall shelf life and to confirm that thermal and hydrolytic degradation pathways, operating alongside the photochemical pathways that are the principal focus of Section 2.2, do not independently compromise product quality within the proposed storage period. Figure 3 summarises the pre-compression, post-compression, analytical, and photostability/shelf-life evaluation categories discussed in this section, and Table 3 consolidates the corresponding formulation strategies and their principal evaluation objectives. [60,49]

Table 3. Formulation Strategies and Corresponding Evaluation Objectives for Riboflavin Dosage Forms

Formulation Strategy	Mechanism / Rationale	Primary Evaluation Objective
Vehicle pH optimisation	Balances aqueous solubility against pH-dependent photodegradation pathway (lumichrome vs lumiflavin)	pH testing at release and on stability; assay/related substances
Caffeine complexation	Forms monomeric complex with riboflavin, inhibiting photolysis, most effective near pH 6	Photostability testing (ICH Q1B); HPLC assay of intact riboflavin
Cyclodextrin inclusion complexation	Encapsulates chromophore within cyclodextrin cavity, reducing direct light absorption/reactivity	Complexation efficiency; photostability comparison vs uncomplexed drug
Liposomal / lipid-based encapsulation	Physical shielding from light and oxygen; combinable with cyclodextrin complexation for additive protection	Particle size, encapsulation efficiency, photostability, release testing
Opaque/amber packaging and film coating	Physically excludes or attenuates incident UV/visible light reaching the dosage form	ICH Q1B photostability comparison of packaged vs unpackaged product
Excipient selection with photoreactivity screening	Avoids excipients (e.g., certain surfactants/poly	Drug-excipient compatibility (FTIR/DSC) plus

© SEP 2026 | IRE Journals | Volume 10 Issue 3 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I3-1722919

Formulation Strategy	Mechanism / Rationale	Primary Evaluation Objective
	mers) shown to accelerate photobleaching	photoreactivity screen
Nanoencapsulation / microencapsulation (food and pharma)	Controlled release, taste masking, protection during processing and GI transit	Particle size/zeta potential, encapsulation efficiency, in-vitro release
Divided oral dosing regimen	Works within the saturable intestinal riboflavin transport ceiling (~20-30 mg/meal)	Bioavailability/absorption assessment; clinical response monitoring

IX. CHALLENGES AND FUTURE PERSPECTIVES

The principal ongoing challenge in riboflavin formulation science remains the reconciliation of adequate photostability with acceptable manufacturing simplicity and cost, since the most effective stabilisation strategies identified in the literature, particularly combined cyclodextrin complexation and liposomal entrapment, add meaningful formulation and manufacturing complexity relative to a simple, uncoated conventional tablet, even though the underlying riboflavin raw material itself remains inexpensive owing to the mature, high-titre microbial fermentation supply chain described in Section 6. A second, related challenge concerns bioavailability optimisation within the constraint of saturable intestinal absorption, which limits the incremental clinical benefit achievable from simply increasing single-dose strength and instead favours divided-dosing regimens or, potentially, delivery technologies capable of achieving more sustained intestinal presentation of the vitamin. [9,56,20]

Looking ahead, continued application of Quality-by-Design methodology to riboflavin dosage form development, explicitly incorporating photostability as a critical quality attribute from the outset rather than as an afterthought, together with further comparative evaluation of emerging encapsulation technologies against simpler and lower-cost packaging-based photoprotection strategies, would help formulators select the most resource-appropriate stabilisation approach for a given clinical and manufacturing context. Continued clinical research further defining the optimal dose, formulation, and patient population for pharmacological applications such as migraine prophylaxis, alongside ongoing refinement of corneal cross-linking protocols, will likewise continue to shape the pharmaceutical requirements placed on riboflavin dosage forms. [61,31,37]

X. CONCLUSION

Riboflavin occupies a distinctive position among pharmaceutical actives: biochemically indispensable, clinically versatile across nutritional, prophylactic, and even ophthalmic-procedural applications, and industrially inexpensive to produce, yet formulation-wise demanding because of its pronounced and well-characterised photolability. This review has drawn together the chemistry and photochemistry, biochemical role, clinical applications, and industrial production of riboflavin, and has set out, in a structured manner, the preformulation, photostabilisation, formulation design, and evaluation considerations that together define sound pharmaceutical practice for riboflavin dosage forms, from conventional tablets through to liposomal and nanoencapsulated delivery systems. [9,61,49]

Future formulation work would benefit from head-to-head comparative stability studies of the principal photostabilisation strategies discussed in this review under standardised ICH Q1B conditions, from continued Quality-by-Design-guided optimisation of tablet and novel delivery platforms, and from further clinical and pharmacoeconomic evaluation of the real-world benefit of improved riboflavin formulation stability for both nutritional supplementation and its emerging pharmacological applications. [61,31]

REFERENCES

[1] Spectroscopic Characterization of the Photolysis of Riboflavin (Vitamin B2) via Time-Resolved Mass Spectrometry and IRMPD Spectroscopy. Journal of Physical Chemistry A. 2025.
[2] Riboflavin metabolism: role in mitochondrial function. Journal of Translational Genetics and Genomics. 2020.
[3] Nutritional Assessment: Riboflavin. Nutritional Assessment educational resource.
[4] Riboflavin Deficiency. In: StatPearls [Point of Care]. Treasure Island (FL): StatPearls Publishing.
[5] Riboflavin Deficiency. In: StatPearls. Treasure Island (FL): StatPearls Publishing; NCBI Bookshelf (NBK470460).
[6] Riboflavin deficiency, epidemiology and clinical features [review]. Annual Review of Nutrition.
[7] Riboflavin - Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington (DC): National Academies Press; NCBI Bookshelf (NBK114322).
[8] Office of Dietary Supplements. Riboflavin - Health Professional Fact Sheet. National Institutes of Health.
[9] Sheraz MA, Kazi SH, Ahmed S, Anwar Z, Ahmad I. Photo, thermal and chemical degradation of riboflavin. Beilstein Journal of Organic Chemistry. 2014;10:1999-2012.
[10] Photodegradation of Riboflavin under Alkaline Conditions: What Can Gas-Phase Photolysis Tell Us about What Happens in Solution? Available from: PubMed Central (PMC8512791).
[11] Photodegradation of Riboflavin - Model Experiments on Photo-oxidation [educational demonstration]. Naturwissenschaften im Unterricht Chemie conference proceedings.
[12] BJOC. Photo, thermal and chemical degradation of riboflavin. Beilstein Journal of Organic Chemistry. 2014;10:1999-2012.
[13] Spectroscopic Characterization of the Photolysis of Riboflavin (Vitamin B2) via Time-Resolved Mass Spectrometry and IRMPD Spectroscopy. Available from: PubMed Central (PMC12169675).
[14] Riboflavin. Food and Nutrition Research journal article on metabolism and transport.
[15] Riboflavin Kinase - an overview. ScienceDirect Topics. Elsevier.
[16] Flavine Mononucleotide - an overview. ScienceDirect Topics. Elsevier.
[17] Nutritional Assessment: Riboflavin [FMN/FAD cofactor roles]. Nutritional Assessment educational resource.
[18] FMN phosphatase and FAD pyrophosphatase in rat intestinal brush borders: role in intestinal absorption of dietary riboflavin. Available from: PubMed (PMID 6120218).
[19] Metabolism and transport of riboflavin and flavocoenzyme [scientific diagram and accompanying text]. ResearchGate.
[20] Riboflavin metabolism: role in mitochondrial function. Journal of Translational Genetics and Genomics. 2020;4:35-46.
[21] Reconstitution in Proteoliposomes of the Recombinant Human Riboflavin Transporter 2 (SLC52A2) Overexpressed in E. coli. Available from: PubMed Central (PMC6769532).
[22] Mitochondrial and Peroxisomal Alterations Contribute to Energy Dysmetabolism in Riboflavin Transporter Deficiency. Available from: PubMed Central (PMC7443020).
[23] Metabolism of FAD, FMN and riboflavin (vitamin B2) in the human parasitic blood fluke Schistosoma mansoni. bioRxiv preprint.
[24] Riboflavin Deficiency - an overview. ScienceDirect Topics. Elsevier.
[25] April 1941. Clinical Manifestations of Ariboflavinosis. American Journal of Public Health. 1941;31(4):344.
[26] Riboflavin Deficiency-Induced Angular Stomatitis and Conjunctivitis in Association with Gut Microbiota Dysbiosis. bioRxiv preprint.
[27] Riboflavin Deficiency: Overview, Riboflavin Requirements, Clinical Features of Deficiency (Ariboflavinosis). Medscape/emedicine.
[28] Riboflavin Inhibits Histamine-Dependent Itch by Modulating Transient Receptor Potential Vanilloid 1 (TRPV1). Available from: PubMed Central (PMC8249943).
[29] What Is Riboflavin Deficiency (Vitamin B2 Deficiency)? Cleveland Clinic Health Library.
[30] Developmental riboflavin deficiency results in structural and functional changes in the neural retina and RPE. Available from: PubMed Central (PMC12301974).

[31] Riboflavin Monograph for Professionals. Drugs.com.
[32] Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology. 1998;50(2):466-470.
[33] High-dose riboflavin for prophylaxis of migraine. Available from: PubMed (PMID 14594097).
[34] The effect of riboflavin on the mean attack frequency, severity, and duration of migraine headaches: A systematic review and dose-response meta-analysis of clinical trials. Available from: PubMed Central (PMC12949614).
[35] Prophylaxis of migraine headaches with riboflavin: A systematic review. Journal of Clinical Pharmacy and Therapeutics. 2017.
[36] Practical supplements for prevention and management of migraine attacks: a narrative review. Frontiers in Nutrition. 2024.
[37] Oral riboflavin versus oral propranolol in migraine prophylaxis: An open label randomized controlled trial. Neurology Asia. 2011;16.
[38] A Review of Keratoconus Cross-Linking Treatment Methods. Available from: PubMed Central (PMC11899953).
[39] Theranostic Guided Riboflavin/UV-A Corneal Cross-linking [clinical trial protocol]. ClinicalTrials.gov (NCT05457647).
[40] Crosslinking with UV-A and riboflavin in progressive keratoconus: From laboratory to clinical practice - Developments over 25 years. Progress in Retinal and Eye Research/ScienceDirect. 2024.
[41] Safety of corneal collagen cross-linking with UV-A and riboflavin in progressive keratoconus. Available from: PubMed (PMID 20164744).
[42] Collagen cross-linking with riboflavin and ultraviolet-A light in keratoconus: One-year results. Available from: PubMed Central (PMC3018104).
[43] Corneal collagen cross-linking (CXL) in thin corneas. Available from: PubMed Central (PMC4657253).
[44] Riboflavin Inhibits Histamine-Dependent Itch by Modulating Transient Receptor Potential Vanilloid 1 (TRPV1) [mechanistic detail]. Available from: PubMed Central (PMC8249943).
[45] Production of Vitamin B2 (Riboflavin) by Microorganisms: An Overview. Frontiers in Bioengineering and Biotechnology. 2020.
[46] Metabolic engineering of riboflavin production in Ashbya gossypii through pathway optimization. Microbial Cell Factories. Available from: PubMed Central (PMC4605130).
[47] Microbial production of riboflavin: Biotechnological advances and perspectives. Biotechnology Advances/ScienceDirect. 2021.
[48] Process for producing riboflavin by fermentation. United States Patent (US 5,334,510).
[49] Improving the Production of Riboflavin by Introducing a Mutant Ribulose 5-Phosphate 3-Epimerase Gene in Bacillus subtilis. Frontiers in Bioengineering and Biotechnology. 2021.
[50] Riboflavin - Vitamin B2. The Nutrition Source, Harvard T.H. Chan School of Public Health.
[51] Photostability Issues in Pharmaceutical Dosage Forms and Photostabilization. AAPS PharmSciTech. 2017.
[52] Sweetman SC, editor. Martindale: The Complete Drug Reference. London: Pharmaceutical Press.
[53] Riboflavin-sensitized photoinduced degradation of donepezil hydrochloride: kinetic and computational insights for pharmaceutical formulation. RSC Advances. 2025.
[54] Photostability and photostabilization of drugs and drug products. Gale Academic OneFile reference collection.
[55] Photoinduced color changes in two different qualities of riboflavin in the solid state and in various tablet formulations: Photoreactivity of biologically active compounds. XX. ResearchGate.
[56] Effect of Caffeine Complexation on the Photolysis of Riboflavin in Aqueous Solution: A Kinetic Study. Chemical and Pharmaceutical Bulletin. 2009;57(12):1363-1370.
[57] Effect of phosphate buffer on the complexation and photochemical interaction of riboflavin and caffeine in aqueous solution: A kinetic study. Journal of Photochemistry and Photobiology A. 2013.
[58] Complex Formation Influence on Reaction Rate I: Effect of Caffeine on Riboflavin Base-Catalyzed Degradation Rate. Journal of Pharmaceutical Sciences/ScienceDirect.

[59] Stabilization of photosensitive materials [liposomal/cyclodextrin riboflavin formulation]. United States Patent (US 6,379,697).
[60] Water in water emulsion stabilized by liposomes developed from whey protein isolate and xanthan gum: Environmental stability and photoprotection effect for riboflavin. Carbohydrate Polymers/ScienceDirect. 2024.
[61] Liposomal Encapsulation in Food Systems: A Review of Formulation, Processing, and Applications. Food Science & Nutrition. 2025.
[62] Nanoencapsulation in functional foods: improving delivery, stability, and sustainability of bioactive compounds. International Journal of Food Science and Technology. Oxford Academic.
[63] Encapsulation of bioactive compounds extracted from date palm seeds (Phoenix dactylifera L.) and their use in functional food. Available from: PubMed Central (PMC9726895).
[64] Liposomes for Nanodelivery Systems in Food Products. In: Springer book chapter.
[65] Micronutrients encapsulation in enhanced nanoliposomal carriers by a novel preparative technology. Available from: PubMed Central (PMC9065329).
[66] Nano-encapsulated Iron and Folic Acid-Fortified Functional Yogurt Enhance Anemia in Albino Rats. Available from: PubMed Central (PMC8058429).
[67] Cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia. United States Patent (US 10,688,196).
[68] Validation of HPLC method for determination of thiamine hydrochloride, riboflavin, nicotinamide and pyridoxine hydrochloride in syrup preparation. ResearchGate. 2011.
[69] Analysis of Vitamin B Compound Tablets by HPLC-UV. Sigma-Aldrich Technical Article.
[70] A Simplified, Specific HPLC Method of Assaying Thiamine and Riboflavin in Mushrooms. Available from: PubMed Central (PMC6378034).
[71] Rapid determination of vitamin B2 (riboflavin) in plasma by HPLC. Available from: PubMed (PMID 20816949).
[72] Quality Control Tests for Tablets and Capsules. Academia.edu educational resource.
[73] A Review on In-Process and Finished Products Quality Control Tests for Tablets According to Pharmacopoeias. Academia.edu educational resource.
[74] Standard Pharmacopoeial Tests Performed On Tablets In Pharmaceutical Manufacturing. ResearchGate. 2025.
[75] Quality Control Tests for Tablets [lecture notes]. College of Pharmacy, University of Baghdad.
[76] Formulation of Ebastine Fast-Disintegrating Tablet Using Coprocessed Superdisintegrants and Evaluation of Quality Control Parameters. Available from: PubMed Central (PMC9135552).
[77] Tablet Evaluation [educational slide presentation]. SlideShare.
[78] Quality Control Tests for Tablets. Pharmapproach.com educational resource.
[79] Indian Pharmacopoeia 2018. Volume III. Ghaziabad: Indian Pharmacopoeia Commission, Government of India, Ministry of Health and Family Welfare.